DTaP-IPV/Hib vaccine

China Human Vaccine Market Insights 2020-2026 Featuring In-Depth Profiles of 22 Companies

Retrieved on: 
Friday, August 7, 2020
Vaccines, Drugs, Vaccination, Medical specialties, RTT, Haemophilus, Diphtheria, Tetanus, Vaccine, HPV vaccine, Pneumococcal vaccine, DTaP-IPV/Hib vaccine

DUBLIN, Aug. 7, 2020 /PRNewswire/ -- The "China Human Vaccine Industry Report, 2020-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 7, 2020 /PRNewswire/ -- The "China Human Vaccine Industry Report, 2020-2026" report has been added to ResearchAndMarkets.com's offering.
  • Human vaccine industry in China (environments, status quo, market demand, market size, import & export, competition pattern);
    Human vaccine market segments in China (market demand, lot releases, competitive landscape);
    22 human vaccine companies (operation, vaccine business, etc.)
  • The Chinese human vaccine market is now occupied by local companies, where the state-owned enterprises command more than a half of the market.
  • Although the Chinese human vaccine market is ruled by local companies, the imported vaccines are largely the extra EPI vaccines (not free, and residents can choose whether they want to be inoculated) such as 13-valent pneumonia vaccine, HPV vaccine and DTaP-IPV/Hib vaccine.